

ECRG2 Antibody
Catalog # ASC11386**Specification**

ECRG2 Antibody - Product Information

Application	WB, IHC
Primary Accession	P58062
Other Accession	AAI09386 , 14211875
Reactivity	Human, Mouse, Rat
Host	Chicken
Clonality	Polyclonal
Isotype	IgY
Application Notes	ECRG2 antibody can be used for detection of ECRG2 by Western blot at 1 µg/mL. Antibody can also be used for immunohistochemistry starting at 5 µg/mL.

ECRG2 Antibody - Additional InformationGene ID **84651****Target/Specificity**

SPINK7; ECRG2 antibody is predicted to not cross-react with other ECRG family members

Reconstitution & Storage

ECRG2 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Precautions

ECRG2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

ECRG2 Antibody - Protein Information**Name** SPINK7**Synonyms** ECG2**Function**

Probable serine protease inhibitor.

Cellular Location


Secreted.

ECRG2 Antibody - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

ECRG2 Antibody - Images



Western blot analysis of ECRG2 in human lung tissue lysate with ECRG2 antibody at 1 μ g/mL in (A) the absence and (B) the presence of blocking peptide.



Immunohistochemistry of ECRG2 in rat lung tissue with ECRG2 antibody at 5 μ g/mL.

ECRG2 Antibody - Background

ECRG2 Antibody: The esophageal cancer-susceptibility gene 2 (ECRG2), also known as SPINK7, is a novel tumor suppressor gene identified from the human esophagus. It interacts directly with metallothionein 2A and urokinase-type plasminogen activator (uPA), and downregulates the activity of uPA, leading to reduced cancer cell migration, invasion and metastasis. ECRG2 forms a complex with uPA and its receptor uPAR, modifying the dynamic association of uPAR with beta1 integrins and disrupting the Src/MAP kinase pathway that normally stimulates cell migration and invasion. ECRG2 may thus represent a novel therapeutic target for cancer.

ECRG2 Antibody - References

Cui Y, Wang J, Zhang X, et al. ECRG2, a novel candidate of tumor suppressor gene in the esophageal carcinoma, interacts directly with metallothionein 2A and links to apoptosis. *Biochem. Biophys. Res. Commun.* 2003; 302:904-15.

Huang G, Hu Z, Li M, et al. ECRG2 inhibits cancer cell migration, invasion and metastasis through the down-regulation of uPA/plasmin activity. *Carcinogenesis* 2007; 28:2274-81

Cheng X, Shen Z, Yin L, et al. ECRG2 regulates cell migration/invasion through the urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway. *J. Biol. Chem.* 2009; 284:30897-906